National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Regdanvimab (RegkironaTM). HTA ID: 21065

Regdanvimab is indicated for the treatment of adults with coronavirus disease 2019 (COVID-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.

 

NCPE Assessment Process Complete
Rapid review commissioned 14/12/2021
Rapid review completed 10/01/2022
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of regdanvimab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.